Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Choice of drug treatment for obesity-related hypertension: where is the evidence?
Autore:
Sharma, AM; Pischon, T; Engeli, S; Scholze, J;
Indirizzi:
Charite Campus Mitte, Berlin, Germany Charite Campus Mitte Berlin Germany arite Campus Mitte, Berlin, Germany Max Delbruck Ctr Mol Med, Berlin, Germany Max Delbruck Ctr Mol Med Berlin Germany ck Ctr Mol Med, Berlin, Germany MDC, Franz Volhard Klin, Charite Campus Buch, D-13122 Berlin, Germany MDCBerlin Germany D-13122 Charite Campus Buch, D-13122 Berlin, Germany
Titolo Testata:
JOURNAL OF HYPERTENSION
fascicolo: 4, volume: 19, anno: 2001,
pagine: 667 - 674
SICI:
0263-6352(200104)19:4<667:CODTFO>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
RANDOMIZED CONTROLLED TRIAL; RENIN-ANGIOTENSIN SYSTEM; PLACEBO-CONTROLLED TRIAL; HIGH BLOOD-PRESSURE; WEIGHT-LOSS; ANTIHYPERTENSIVE THERAPY; BETA-BLOCKERS; INSULIN SENSITIVITY; DIABETES-MELLITUS; ADIPOSE-TISSUE;
Keywords:
obesity; body weight; weight gain; hypertension; therapy; treatment;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
95
Recensione:
Indirizzi per estratti:
Indirizzo: Sharma, AM MDC, Franz Volhard Klin, Charite Campus Buch, Wiltbergstr 50, D-13122 Berlin, Germany MDC Wiltbergstr 50 Berlin Germany D-13122 3122 Berlin, Germany
Citazione:
A.M. Sharma et al., "Choice of drug treatment for obesity-related hypertension: where is the evidence?", J HYPERTENS, 19(4), 2001, pp. 667-674

Abstract

Hypertension and obesity are common medical conditions independently associated with increased cardiovascular risk. Many large epidemiological studies have demonstrated associations between body mass index and blood pressure, and there is evidence to suggest that obesity is a causal factor in the development of hypertension in obese individuals, Consequently, all hypertension management guidelines consider weight reduction as a first step in themanagement of increased blood pressure in obese individuals. Weight reduction may be achieved by behaviour modification, diet and exercise, or by theuse of anti-obesity medications. However, the long-term outcomes of weightmanagement programmes for obesity are generally poor, and most hypertensive patients will require antihypertensive drug treatment. Some classes of antihypertensive agents may have potentially unwanted effects on some of the metabolic and haemodynamic abnormalities that link obesity and hypertension, yet most hypertension guidelines fail to provide specific advice on the pharmacological management of obese patients. This may be because there are currently no studies examining the efficacy of specific antihypertensive agents in reducing mortality in obese hypertensive patients. This paper reviews the theoretical reasons for the differential use of the major classes ofantihypertensive agents in the pharmacological management of obesity-related hypertension and also considers the potential role of anti-obesity agents. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 20:20:56